ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $25.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price increased by Stifel Nicolaus from $24.00 to $25.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the stock. Royal Bank Of Canada lifted their target price on shares of ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday, June 29th. Citigroup boosted their target price on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, June 29th. HC Wainwright lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings downgraded ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Thirteen investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD opened at $24.83 on Tuesday. The stock has a market cap of $4.25 billion, a PE ratio of 11.29, a price-to-earnings-growth ratio of 17.31 and a beta of 0.80. ACADIA Pharmaceuticals has a fifty-two week low of $19.69 and a fifty-two week high of $28.35. The stock’s 50-day moving average is $23.16 and its two-hundred day moving average is $23.24.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company had revenue of $268.10 million during the quarter, compared to analysts’ expectations of $280.25 million. During the same period last year, the company earned $0.11 earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, equities research analysts anticipate that ACADIA Pharmaceuticals will post 0.39 earnings per share for the current year.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the completion of the sale, the executive vice president owned 66,145 shares of the company’s stock, valued at $1,441,299.55. The trade was a 5.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James Kihara sold 5,401 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the sale, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This trade represents a 18.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 10,239 shares of company stock valued at $219,813 over the last quarter. 26.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its holdings in ACADIA Pharmaceuticals by 9.0% during the fourth quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock valued at $211,296,000 after purchasing an additional 655,257 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of ACADIA Pharmaceuticals by 47.3% in the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after buying an additional 1,073,834 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company’s stock worth $86,539,000 after buying an additional 106,807 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of ACADIA Pharmaceuticals by 8.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock worth $70,222,000 after buying an additional 234,186 shares during the period. Finally, Marshall Wace LLP grew its stake in ACADIA Pharmaceuticals by 19.8% in the 3rd quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company’s stock valued at $50,339,000 after buying an additional 389,170 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.